KEYNOTE-590 Trial: Pembrolizumab Improves OS in Esophageal Cancer

Published by Jason Butcher on

Overall survival (OS) is improved when patients with previously untreated advanced esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC) or esophagogastric junction adenocarcinoma (EGJ) receive the checkpoint inhibitor pembrolizumab with chemotherapy rather than chemotherapy alone, according to data from the phase 3 KEYNOTE-590 trial. 

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.